MedTrace Logo

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

NCT05481658 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-10

No results posted yet for this study

Summary

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.

Conditions

  • Cutaneous Metastases

Interventions

DRUG

Diphencyprone (DPCP)

topical immunomodulator

Sponsors & Collaborators

  • Nicholas Gulati

    lead OTHER

Principal Investigators

  • Nicholas Gulati, MD, PhD · Icahn School of Medicine at Mount Sinai

  • Philip Friedlander, MD, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2029-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481658 on ClinicalTrials.gov